trending Market Intelligence /marketintelligence/en/news-insights/trending/1BEy6tinzpozqueU__5trA2 content esgSubNav
In This List

US FDA approves Roche's lung cancer companion diagnostic

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


US FDA approves Roche's lung cancer companion diagnostic

The U.S. Food and Drug Administration approved Roche Holding Ltd.'s VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify anaplastic lymphoma kinase-positive non-small cell lung cancer patients eligible for treatment with Novartis AG's Zykadia drug.

The in vitro diagnostic assay will be used to detect the anaplastic lymphoma kinase protein in non-small cell lung carcinoma tissue on BenchMark XT or BenchMark ULTRA automated staining instrument. It is the only immunohistochemistry test approved by the FDA as a companion diagnostic for Zykadia.